$-0.32 EPS Expected for Verastem Inc (VSTM)

October 29, 2017 - By Clifton Ray

 $ 0.32 EPS Expected for Verastem Inc (VSTM)
Investors sentiment increased to 1.17 in Q2 2017. Its up 0.07, from 1.1 in 2017Q1. It is positive, as 5 investors sold Verastem Inc shares while 18 reduced holdings. 13 funds opened positions while 14 raised stakes. 8.68 million shares or 12.61% more from 7.71 million shares in 2017Q1 were reported.
Grt Cap Ptnrs Ltd Liability owns 22,405 shares for 0.03% of their portfolio. 1.19 million are held by Deer Vii Ltd. Artal owns 500,000 shares or 0.02% of their US portfolio. Blackrock owns 394,247 shares. Rbf Capital Llc stated it has 0.01% of its portfolio in Verastem Inc (NASDAQ:VSTM). Federated Invsts Incorporated Pa holds 1,293 shares. Advisory Svcs Ntwk Ltd Llc holds 0.01% or 17,825 shares. Raymond James & Associate reported 12,643 shares. 223,290 were reported by Jacobs Levy Equity Mgmt. Bridgeway Cap Mngmt reported 231,500 shares or 0.01% of all its holdings. Dimensional Fund Advisors Lp holds 289,828 shares or 0% of its portfolio. Bancorp Of America Corp De accumulated 1,500 shares or 0% of the stock. California Public Employees Retirement Sys invested in 0% or 91,300 shares. Morgan Stanley reported 0% of its portfolio in Verastem Inc (NASDAQ:VSTM). Tower Rech Capital Lc (Trc) owns 5,027 shares or 0% of their US portfolio.

Since May 15, 2017, it had 1 buy, and 0 sales for $73,500 activity.

Analysts expect Verastem Inc (NASDAQ:VSTM) to report $-0.32 EPS on November, 6.They anticipate $0.11 EPS change or 52.38 % from last quarter’s $-0.21 EPS. After having $-0.36 EPS previously, Verastem Inc’s analysts see -11.11 % EPS growth. The stock increased 5.92% or $0.21 on October 27, reaching $3.76. About 279,541 shares traded. Verastem Inc (NASDAQ:VSTM) has risen 71.53% since October 29, 2016 and is uptrending. It has outperformed by 54.83% the S&P500.

Verastem Inc (NASDAQ:VSTM) Ratings Coverage

Among 10 analysts covering Verastem (NASDAQ:VSTM), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Verastem had 26 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, September 25 by Cantor Fitzgerald. The company was downgraded on Monday, September 28 by Mizuho. On Monday, September 28 the stock rating was downgraded by TH Capital to “Neutral”. The rating was downgraded by Cantor Fitzgerald on Tuesday, September 29 to “Hold”. The stock has “Buy” rating by Oppenheimer on Tuesday, August 8. The firm has “Buy” rating by Oppenheimer given on Wednesday, August 16. The stock of Verastem Inc (NASDAQ:VSTM) has “Hold” rating given on Thursday, June 8 by Cantor Fitzgerald. The firm has “Buy” rating by Oppenheimer given on Friday, June 16. The rating was maintained by Oppenheimer with “Buy” on Sunday, June 4. Raymond James downgraded the stock to “Outperform” rating in Tuesday, September 29 report.

Verastem, Inc. is a biopharmaceutical company. The company has market cap of $139.09 million. The Firm is focused on discovering and developing drugs to improve outcomes for patients with cancer. It currently has negative earnings. The Firm operates in the segment of developing drugs for the treatment of cancer.

More news for Verastem Inc (NASDAQ:VSTM) were recently published by: Businesswire.com, which released: “Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer” on October 11, 2017. Businesswire.com‘s article titled: “Verastem Pays Milestone Payment to Infinity Pharmaceuticals” and published on October 17, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com